Efficacy, safety and tolerability of a combination of electrolyte with citicoline (Neurocitin®) in patients with acute ischemic stroke: first results of the study

I.I. Titov

Abstract


Background. Acute ischemic stroke is a global health problem, since most of the patients die or become disabled. In this regard, it continues to be relevant to search for new effective treatments for this disease. We have initiated our own study to assess one of the most famous cerebroprotectors (citicoline) in combination with electrolyte (Neurocitin®) in such acute cerebral accidents. Materials and ­methods. In an open, randomized, controlled trial, it is planned to include 55 patients of both sexes aged 25 to 75 years with a diagnosis of acute ischemic stroke. The control group would consist of 25 patients with standard therapy of acute ischemic stroke by Order of the Ministry of Health of Ukraine N 602 (without cerebroprotectors). Study group will include 30 patients with the same standard therapy + Neurocitin® 100 ml 2 times a day for 14 days. The primary efficacy outcomes included: the score on the NIHSS scale, Barthel index and Rankin scale by day 14 of treatment; content of neuron specific enolase (the marker of neuronal damage), the value of bispectral index (the marker of electrical activity of the cortex) by day 14 of treatment, the measure of cerebral oximetry (the marker of brain oxygenation) by day 5 of treatment; the state of cerebral hemodynamics according to Doppler ultrasound of brain vessels by discharge. Results. By the time of preparation of this article, both the study and control groups of the research included 20 patients each. By day 14 of treatment, the decrease of neuron specific enolase content was 2.73 times greater in the study group (with Neurocitin® (electrolyte combination of sodium, potassium, calcium and chlorine, as well as lactate and citicoline)) compared with the controls, and was close to reach normal. By day 14 of treatment, the increase of bispectral index was 64.9 % higher in the study group than in the control one, and its value practically reached normal. By day 5 of treatment, the increase of measure of cerebral oximetry was 49.6 % higher in the study group compared to the controls, and its value reached the norm. In many cases, an improvement in the group of Neurocitin® developed earlier compared to the treatment without cerebroprotector. Conclusions. Preliminary results of our study suggest that the inclusion of Neurocitin® (electrolyte combination of sodium, potassium, calcium and chlorine, as well as lactate and citicoline) into the scheme of treatment of acute ischemic stroke leads to a significantly more rapid reduction of neuronal damage, restore the electrical activity of the cortex and brain oxygenation compared to the therapy without cerebroprotector. In many cases, these effects are observed at an earlier date. Preliminary results of the study indicate the desirability of Neurocitin® inclusion into the current protocols of treatment for acute ischemic stroke.


Keywords


Neurocitin®; citicoline; acute ischemic stroke; neuron specific enolase; bispectral index; cerebral oximetry; comprehensive neuroprotection

References


Мищенко Т.С. Лечение больных ишемическим инсультом // Здоров’я України. — 2015. — http://health-ua.com

Главный специалист МЗ Украины о профилактике и лечении мозговых инсультов // http://medinfo.ua

Академия инсульта — 2015: время действовать! // Здоров’я України. — 2015 (тематичний номер). — С. 14-16.

Тромболизис при ишемическом инсульте — реканализация, нейропротекция и последующая каротидная эндартерэктомия / Евтушенко С.К., Шепотинник Е.В., Родин Ю.В., Дюба Д.Ш. // Журнал неврології ім. Б.М. Маньковського. — 2013. — Т. 1, № 2. — С. 69-72.

Тітов І.І. Ключові питання інтенсивної терапії хворих з гострими мозковими катастрофами // III Міжнародний конгрес з інфузійної терапії — 2016. — https://www.youtube.com/watch?v = ex274I1TXJU

Наказ МОЗ України від 03.08.2012 № 602 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при ішемічному інсульті» // http://www.moz.gov.ua

Sahota P., Savitz S.I. Investigational Therapies for Ischemic Stroke: Neuroprotection and Neurorecovery // Neurotherapeutics. — 2011. — V. 8, № 3. — P. 434-451.

Secades J.J., Lorenzo J.L. Citicoline: pharmacological and clinical review, 2006 update // Methods Find. Exp. Clin. Pharmacol. — 2006. — V. 28 (Suppl. B). — P. 1-56.

Álvarez-Sabín J., Román G.C. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke // Brain Sciences. — 2013. — V. 3, № 3. — P. 1395-1414.

Stroke management / Warburton E., Alawneh J.A., Clatworthy P.L., Morris R.S. // BMJ Clin. Evid. — 2011. — V. 2011, pii: 0201.

Overgaard K. The effects of citicoline on acute ischemic stroke: a review // J. Stroke Cerebrovasc. Dis. — 2014. — V. 23, № 7. — P. 1764-1769.

Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials / Secades J.J., Alvarez-Sabín J., Castillo J. et al. // J. Stroke Cerebrovasc. Dis. — 2016. — V. 25, № 8. —

P. 1984-1996.

Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials / Shi P.Y., Zhou X.C., Yin X.X. et al. // J. Huazhong Univ. Sci. Technolog. Med. Sci. — 2016. — V. 36, № 2. — P. 270-277.

Al-Rawi N.H., Atiyah K.M. Salivary neuron specific enolase: an indicator for neuronal damage in patients with ischemic stroke and stroke-prone patients // Clin. Chem. Lab. Med. — 2009. — V. 47, № 12. — P. 1519-1524.

Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke / Wunderlich M.T., Lins H., Skalej M. et al. // Clin. Neurol. Neurosurg. — 2006. — V. 108, № 6. — P. 558-563.

S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke / Missler U., Wiesmann M., Friedrich C., Kaps M. // Stroke. — 1997. — V. 28, № 10. — P. 1956-1960.

Li Y., Wang X., Yang Z. Neuron-specific enolase in patients with acute ischemic stroke and related dementia // Chin. Med. J. (Engl). — 1995. — V. 108, № 3. — P. 221-223.

Sulter G., Elting J.W., De Keyser J. Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke // Neurosci. Lett. — 1998. — V. 253, № 1. —

P. 71-73.

Correlative study between neuron-specific enolase and blood sugar level in ischemic stroke patients / Pandey A., Saxena K., Verma M., Bharosay A. // J. Neurosci. Rural. Pract. — 2011. — V. 2, № 1. — P. 50-54.

Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke / González-García S., González-Quevedo A., Peña-Sánchez M. et al. // J. R. Coll. Physicians Edinb. — 2012. — V. 42, № 3. — P. 199-204.

Serum neuron-specific enolase, carnosinase, and their ratio in acute stroke. An enzymatic test for predicting outcome? / Butterworth R.J., Wassif W.S., Sherwood R.A. et al. // Stroke. — 1996. — V. 27, № 11. — P. 2064-2068.

Pandey A., Shrivastava A.K., Saxena K. Neuron specific enolase and c-reactive protein levels in stroke and its subtypes: correlation with degree of disability // Neurochem. Res. — 2014. — V. 39, № 8. — P. 1426-1432.

Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit / Singh H.V., Pandey A., Shrivastava A.K. et al. // Clin. Chim. Acta. — 2013. — V. 419. — P. 136-138.

Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients / González-García S., González-Quevedo A., Fernández-Concepción O. et al. // Clin. Biochem. — 2012. — V. 45, № 16–17. — P. 1302-1307.

Islam N., Ullah E., Akhtar N. Correlation between serum neuron specific enolase and functional neurological outcome in patients of acute ischemic stroke / Zaheer S., Beg M., Rizvi I. et al. // Annals of Indian Academy of Neurology. — 2013. — V. 16, № 4. — P. 504-508.

Correlation of Brain Biomarker Neuron Specific Enolase (NSE) with Degree of Disability and Neurological Worsening in Cerebrovascular Stroke / Bharosay A., Bharosay V.V., Varma M. et al. // Indian J. Clin. Biochem. — 2012. — V. 27, № 2. —

P. 186-190.

Prognostic value of somatosensory evoked potentials, neuron-specific enolase, and S100 for short-term outcome in ischemic stroke / Haupt W.F., Chopan G., Sobesky J. et al. // J. Neurophysiol. — 2016. — V. 115, № 3. — P. 1273-1278.

Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke / Brea D., Sobrino T., Blanco M. et al. // Clin. Chem. Lab. Med. — 2009. — V. 47, № 12. — P. 1513-1518.

The second elevation of neuron-specific enolase peak after ischemic stroke is associated with hemorrhagic transformation / Kim B.J., Kim Y.J., Ahn S.H. et al. // J. Stroke Cerebrovasc. Dis. — 2014. — V. 23, № 9. — P. 2437-2443.

Anand N. Stead L.G. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review // Cerebrovasc. Dis. — 2005. — V. 20, № 4. — P. 213-219.

Kaca-Oryńska M., Tomasiuk R., Friedman A. Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke // Neurol. Neurochir. Pol. — 2010. — V. 44, № 5. — P. 459-463.

Myles P.S. Bispectral index monitoring in ischemic-hypoxic brain injury // J. Extra. Corpor. Technol. — 2009. — V. 41, № 1. — P. 15-19.

Bispectral Index Changes during Acute Brainstem TIA/Ischemia / Bleeker C.P., Smits B., Vos P.E., Mourisse J.M. // Case Rep. Med. — 2010. — V. 2010, Article ID 697185.

Bigham C., Bigham S., Jones C. Does the bispectral index monitor have a role in intensive care? // J. Intensive Care Soc. — 2012. — 13. — 314-9.

Monitoring of cortical activity postreperfusion. A powerful tool for predicting clinical response immediately after recanalization / Flores A., Ribó M., Rubiera M. et al. // J. Neuroimaging. — 2015. — V. 25, № 2. — P. 257-262.

Leggat C.S., Fischer G.W. Early detection of an acute cerebral event during cardiopulmonary bypass using a bispectral index monitor // Semin. Cardiothorac. Vasc. Anesth. — 2008. — V. 12, № 1. — P. 80-82.

The bispectral index in the diagnosis of perioperative stroke: a case report and discussion / Welsby I.J., Ryan J.M., Booth J.V. et al. // Anesth. Analg. — 2003. — V. 96, № 2. —

P. 435-437.

Murkin J.M., Arango M. Near-infrared spectroscopy as an index of brain and tissue oxygenation // Br. J. Anaesth. — 2009. — V. 103 (Suppl. 1). — P. i3-i13.

Validation of frontal near-infrared spectroscopy as noninvasive bedside monitoring for regional cerebral blood flow in brain-injured patients / Taussky P., O’Neal B., Daugherty W.P. et al. // Neurosurg. Focus. — 2012. — V. 32, № 2. — P. E2.

The evaluation of cerebral oxygenation by oximetry in patients with ischaemic stroke / Demet G., Talip A., Nevzat U. et al. // J. Postgrad. Med. — 2000. — V. 46, № 2. — P. 70-74.

Brain oxygen supply in the residual period of ischemic stroke / Kamenskaia O.V., Levicheva E.N., Loginova I.Iu., Karpenko A.A. // Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova. — 2012. — V. 112, № 8 (Pt. 2). — P. 20-24.

Cerebral oximetry with cerebral blood volume index in detecting pediatric stroke in a pediatric ED / Abramo T.J., Harris Z.L., Meredith M. et al. // Am. J. Emerg. Med. — 2015. — V. 33, № 11. — P. 1622-1629.

Noninvasive cerebral oximetry during endovascular therapy for acute ischemic stroke: an observational study / Hametner C., Stanarcevic P., Stampfl S. et al. // J. Cereb. Blood Flow Metab. — 2015. — V. 35, № 11. — P. 1722-1728.

Outcome improvement and cost reduction in an increasingly morbid cardiac surgery population / Goldman S.M., Sutter F.P., Wertan M.A. et al. // Semin. Cardiothorac. Vasc. Anesth. — 2006. — V. 10, № 2. — P. 171-175.

Murkin J.M. Is it better to shine a light, or rather to curse the darkness? Cerebral near-infrared spectroscopy and cardiac surgery // Eur. J. Cardiothorac. Surg. — 2013. — V. 43, № 6. — P. 1081-1083.

Cerebral near-infrared spectroscopy monitoring and neurologic outcomes in adult cardiac surgery patients: a systematic review / Zheng F., Sheinberg R., Yee M.S. et al. // Anesth. Analg. — 2013. — V. 116, № 3. — P. 663-676.

Cerebral monitoring in patients undergoing carotid endarterectomy using a triple assessment technique / Ali A.M., Green D., Zayed H. et al. // Interact. Cardiovasc. Thorac. Surg. — 2011. — V. 12, № 3. — P. 454-457.

The value of near-infrared spectroscopy measured cerebral oximetry during carotid endarterectomy in perioperative stroke prevention. A review / Pennekamp C.W., Bots M.L., Kappelle L.J. et al. // Eur. J. Vasc. Endovasc. Surg. — 2009. — V. 38, № 5. — P. 539-545.

Cerebral oximetry monitoring during carotid endarterectomy: effect of carotid clamping and shunting / Cuadra S.A., Zwerling J.S., Feuerman M. et al. // Vasc. Endovascular. Surg. — 2003. — V. 37, № 6. — P. 407-413.

Continuous cerebral blood flow autoregulation monitoring in patients undergoing liver transplantation / Zheng Y., Villamayor A.J., Merritt W. et al. // Neurocrit. Care. — 2012. — V. 17, № 1. —

P. 77-84.

Cerebrovascular effects of hemodialysis in chronic kidney disease / Prohovnik I., Post J., Uribarri J. et al. // J. Cereb. Blood Flow Metab. — 2007. — V. 27, № 11. — V. 1861-1869.




DOI: https://doi.org/10.22141/2224-0713.1.87.2017.96539

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru